Clinical trials in Tanzania

The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

This study looks at a new drug, Rilzabrutinib, for people aged 10-65 with sickle cell disease. We'll see how well it works and if it's safe compared to a dummy pill to help reduce painful crises.